Search

Your search keyword '"Aliakbar Saboor-Yaraghi"' showing total 4 results
Start Over Author "Aliakbar Saboor-Yaraghi"
4 results on '"Aliakbar Saboor-Yaraghi"'

1. Effect of Vitamin A Supplementation on Fatigue and Depression in Multiple Sclerosis Patients: A Double-blind Placebo-controlled Clinical Trial

Author

Sama Bitarafan, Aliakbar Saboor-Yaraghi, Mohammad-Ali Sahraian, Danesh Soltani, Shahriar Nafissi, Mansoureh Togha, Nahid Beladi Moghadam, Tina Roostaei, Niyaz Mohammadzadeh Honarvar, and Mohammad-Hossein Harirchian

Subjects
Depression, Fatigue, Multiple sclerosis, Vitamin A, Medicine
Abstract

Decreasing the population and activation of inflammatory T helper cells in multiple sclerosis (MS) patients using vitamin A derivatives (retinoic acids) has been well documented. The present study determined the effect of vitamin A supplementation on psychiatric signs in MS patients. The subjects were 101 relapsing-remitting MS patients enrolled in a placebo-controlled randomized clinical trial. The treatment group was administered 25000 IU/d retinyl palmitate (RP) for 6 months followed by 10000 IU/d RP for another 6 months. The results for baseline characteristics, modified fatigue impact scale and Beck Depression Inventory-II were recorded at the beginning and end of the one-year study. The non-normal distribution data was compared between groups using a nonparametric test and normal distribution data was analyzed using a parametric test. (ClinicalTrials.gov Identifiers: NCT01417273). The results showed significant improvement in the treatment group for fatigue (p=0.004) and depression (p=0.01). Vitamin A supplementation helped during interferon therapy in the treatment process and improved psychiatric outcomes for anti-inflammatory mechanisms.

Published
2016

3. Detection of Silver Nanoparticles Internalization into Petunia, Petunia hybrida, Isolated Protoplasts

Author

Mehdi Farhoodi, Sarah Jafari Rad, Aliakbar Saboor Yaraghi, Roohangiz Naderi, and Mina Nemati

Subjects
biology, Chemistry, media_common.quotation_subject, General Engineering, Silver Nano, Nanotechnology, Protoplast, biology.organism_classification, Endocytosis, Petunia, Silver nanoparticle, Cell membrane, medicine.anatomical_structure, Biophysics, medicine, Internalization, Intracellular, media_common
Abstract

The use of nanoparticles has spannded many divisions of biological fields including sensors, drug delivery and clinical diagnosis. These functions all based on the most important action in cells called Endocytosis. The study of endocytosis in higher order plants remained inactive for a long period of time. In this work we use Silver Nano Particles (S.N.Ps) as a endocytosic substances were incubated by isolated protoplast of petunia .Concurrently, with the study of internalization, their appear aggregation inter and intracellular were investigated by Transmissions Electron Microscopy (TEM). Results and observations showed that the S.N.Ps crossed the cell membrane and internalized in to the cells. It can be assumed that the particles with the organic functionality – PEG coated – were internalized by the petunia protoplasts.

Published
2012
Full Text
View/download PDF

4. Impact of Vitamin A Supplementation on Disease Progression in Patients with Multiple Sclerosis

Author

Sama, Bitarafan, Aliakbar, Saboor-Yaraghi, Mohammad-Ali, Sahraian, Shahriar, Nafissi, Mansoureh, Togha, Nahid, Beladi Moghadam, Tina, Roostaei, Fereydoun, Siassi, Mohammad-Reza, Eshraghian, Hossein, Ghanaati, Sima, Jafarirad, Behrouz, Rafiei, and Mohammad-Hossein, Harirchian

Subjects
Adult, Male, Retinyl Esters, Iran, Middle Aged, Magnetic Resonance Imaging, Disability Evaluation, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Treatment Outcome, Double-Blind Method, Disease Progression, Humans, Female, Diterpenes, Vitamin A
Abstract

Many studies have shown that active vitamin A derivatives suppress the formation of pathogenic T cells in multiple sclerosis (MS) patients. The aim of the present study is to determine the impact of vitamin A on disease progression in MS patients.A total of 101 relapsing-remitting MS (RRMS) patients were enrolled in a 1-year placebo-controlled randomized clinical trial. The treated group received 25000 IU/d retinyl palmitate for six month followed by 10000 IU/d retinyl palmitate for another six month. The results of the expanded disability status scale (EDSS) and multiple sclerosis functional composite (MSFC) were recorded at the beginning and the end of the study. The relapse rate was recorded during the intervention. Patients underwent baseline and follow up brain MRIs.The results showed "Mean ± SD" of MSFC changes in the treated group was (-0.14 ± 0.20) and in the placebo group was (-0.31 ± 0.19). MSFC was improved significantly (P0.001) in the treatment group. There were no significant differences between the "Mean ± SD" of EDSS changes in the treated (0.07 ± 0.23) and placebo (0.08 ± 0.23) groups (P = 0.73). There were also no significant differences between the "Mean ± SD" of annualized relapse rate in the treated group (-0.36 ± 0.56) and placebo (-0.53 ± 0.55) groups (P = 0.20). The "Mean ± SD" of enhanced lesions in the treatment (0.4 ± 1.0) and in the placebo (0.2 ± 0.6) groups were not significantly different (P = 0.26). Volume of T2 hyperintense lesions "Mean ± SD" was not significantly different between treatment (45 ± 137) and placebo (23 ± 112) groups after intervention (P = 0.23).Vitamin A improved total MSFC score in RRMS patients, but it did not change EDSS, relapse rate and brain active lesions.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results